IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug
Exelixis (EXEL) shares fell after the FDA delayed approval of its colon cancer treatment, a combination of zanzalintinib and Roche's (RHHBY) Tecentriq, by three months. Analyst Andy Hsieh from William Blair believes rejection is unlikely, as the treatment showed survival benefits.
How this was made
The 30-second read
Why it matters
The delay pushes the expected market launch, reducing near-term revenue forecasts and prompting a sell-off.
Market read
Regulatory setback for a mid-cap biotech likely triggers a short-term price decline and may influence sector sentiment.
What to watch
Roche's involvement may mitigate some risk if they continue to support the combo.
Background
Exelixis is an IBD 50 biotech; the FDA delay was announced Friday after a review of the colon cancer combination therapy.
Ticker impact
FDA delayed approval of Exelixis' colon cancer combo by three months, causing the stock to fall out of its buy zone.
Potential 5-10% decline over the next week.
Regulatory delay is a material catalyst for a biotech; market typically reacts negatively to extended timelines.
Market effects
May weigh on other oncology biotech stocks awaiting FDA decisions.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond investors tracking US biotech pipelines.
Counterpoint
Delay could allow additional data collection, potentially strengthening the eventual label.
Key entities
- companyExelixis
US-listed biotech developing the delayed colon cancer treatment.
- companyRoche
Partner providing Tecentriq in the combination therapy.
